Chickasaw Capital Management LLC Trims Position in Pfizer Inc. (NYSE:PFE)

Chickasaw Capital Management LLC cut its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 4.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 15,640 shares of the biopharmaceutical company’s stock after selling 645 shares during the quarter. Chickasaw Capital Management LLC’s holdings in Pfizer were worth $801,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer in the first quarter worth $29,000. Karp Capital Management Corp purchased a new stake in shares of Pfizer in the third quarter worth $27,000. Delos Wealth Advisors LLC increased its stake in shares of Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 400 shares in the last quarter. Legend Financial Advisors Inc. purchased a new stake in shares of Pfizer in the third quarter worth $42,000. Finally, New Millennium Group LLC purchased a new stake in shares of Pfizer in the second quarter worth $53,000. 67.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Pfizer in a research note on Monday, March 6th. They set a “hold” rating and a $43.00 target price for the company. SVB Leerink cut their target price on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a research note on Wednesday, February 1st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 target price for the company in a research note on Tuesday, February 7th. Credit Suisse Group cut their target price on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Finally, The Goldman Sachs Group raised shares of Pfizer from a “neutral” rating to a “buy” rating and raised their target price for the company from $47.00 to $60.00 in a research note on Tuesday, December 13th. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $50.38.

Pfizer Price Performance

PFE stock opened at $40.10 on Friday. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The company has a fifty day simple moving average of $43.26 and a two-hundred day simple moving average of $46.03. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business earned $1.08 EPS. Analysts anticipate that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.